


## GBR 12935 dihydrochloride

<b>Cat. No.:</b>	HY-12242
<b>CAS No.:</b>	67469-81-2
<b>Molecular Formula:</b>	C <sub>28</sub> H <sub>36</sub> Cl <sub>2</sub> N <sub>2</sub> O
<b>Molecular Weight:</b>	487.5
<b>Target:</b>	Dopamine Transporter
<b>Pathway:</b>	Neuronal Signaling
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 25 mg/mL (51.28 mM; Need ultrasonic)					
	H <sub>2</sub> O : 7.14 mg/mL (14.65 mM; ultrasonic and warming and heat to 60°C)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		2.0513 mL	10.2564 mL	20.5128 mL
<b>5 mM</b>			0.4103 mL	2.0513 mL	4.1026 mL	
	<b>10 mM</b>		0.2051 mL	1.0256 mL	2.0513 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.13 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.13 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.13 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	GBR 12935 dihydrochloride is a potent, and selective dopamine reuptake inhibitor, with the binding constant (K <sub>d</sub> ) of 1.08 nM in COS-7 cells. GBR 12935 dihydrochloride stimulates the locomotion activity in different mice strains but fails to induce stereotypy. Thus, GBR 12935 dihydrochloride also prevents the d-Fenfluramine-induced head-twitch response in mice <sup>[1][2][3][4]</sup> .
<b>In Vitro</b>	GBR 12909 (10-100 nM) also shows a high affinity for CYP2D6 with the K <sub>d</sub> value of 42.2 nM, lower than the affinity for dopamine transporter. The binding effect can be reduced by <a href="#">Quinidine</a> (HY-B1751) and <a href="#">Quinine</a> (HY-D0143), which are the specific and potent inhibitors of CYP2D enzymatic activities <sup>[1]</sup> .

GBR 12935 dihydrochloride (10 nM; 2 min) increases the extracellular levels of dopamine to approximately 400% of basal during the application in the nucleus accumbens<sup>[2]</sup>.  
GBR 12935 dihydrochloride (100 μM; 60 min) increases extracellular levels of dopamine compared with levels for artificial cerebrospinal fluid (ACSF) by local perfusion for 60 min<sup>[2]</sup>.  
GBR 12935 dihydrochloride (1-9 nM) dose-dependently inhibits active uptake of [<sup>3</sup>H]dopamine in homogenates of the nucleus accumbens<sup>[2]</sup>.  
Co-perfusion of 100 μM GBR 12935 dihydrochloride with either 100 μM [Sulpiride](#) (HY-B1019) or [Raclopride](#) (HY-103414) produces a significant reduction in the GBR 12935 dihydrochloride induced increase in the extracellular levels of dopamine to basal levels<sup>[2]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

GBR 12935 dihydrochloride (1-32 mg/kg; repeat injection; 7 d) elevates locomotion activity to a greater extent in C57BL/6J mice than DBA/2J mice, and (10 mg/kg; injection; 7 d) results few mice sensitized to cocaine-induced stereotypy with repeated injections<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male DBA/2J and C57BL/6J mice (22-30 g) <sup>[3]</sup>
Dosage:	1.0, 3.2, 10, 32 mg/kg
Administration:	Repeat injection; for 7 days
Result:	Elevated locomotion activity to a greater extent in C57BL/6J mice than DBA/2J mice. No stereotypy was induced by an eighth day challenge of 10 mg/kg GBR 12935 dihydrochloride in mice pretreated with seven daily injections of either 32 mg/kg cocaine or saline.

## REFERENCES

- [1]. Hiroi T, et al. Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. *Biochem Pharmacol.* 1997 Jun 15;53(12):1937-9.
- [2]. Rahman S, et al. Negative interaction of dopamine D2 receptor antagonists and GBR 12909 and GBR 12935 dopamine uptake inhibitors in the nucleus accumbens. *Eur J Pharmacol.* 2001 Feb 23;414(1):37-44.
- [3]. Tolliver BK, et al. Comparison of cocaine and GBR 12935: effects on locomotor activity and stereotypy in two inbred mouse strains. *Pharmacol Biochem Behav.* 1994 Jul;48(3):733-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA